ArticlePloS one2018
Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review.Frontiers in public health · 2022Pooled it
- Hepatocellular carcinoma surveillance: a health economic evaluation.Clinical and molecular hepatology · 2026Review
- Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis.Digestive diseases (Basel, Switzerland) · 2025Article
- Cost of illness for colorectal cancer in Japan - a time trend and future projections (1996-2035) based on governmental statistics.BMC health services research · 2023Article
- Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.PloS one · 2023Article
- Cost of illness in a super-aged society-comparison of breast, lung, and prostate cancer in Japan.BMC geriatrics · 2022Article
- The population-level economic burden of liver cancer in China, 2019-2030: prevalence-based estimations from a societal perspective.Cost effectiveness and resource allocation : C/E · 2022Article
- Effect of Mycophenolate Mofetil Therapy on Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Population-Based Cohort Study.Journal of clinical medicine · 2021Article
- Comparison of the cost of illness of primary liver cancer between Japan and Taiwan.Health economics review · 2020Article
- Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles.Japanese journal of radiology · 2020Article
- Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.PharmacoEconomics · 2020Review
- Comparative Immunohistochemical Analysis of Clinicopathological Subgroups in Hepatocellular Carcinomas from Japan and Indonesia.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the fifth leading cause of death in Japan. The aim of this study was to calculate the social burden of HCC using the cost of illness (COI) method, and to identify the key factors driving changes in the economic burden of HCC.
methodsUtilizing government-based statistical nationwide data, the cost of illness (COI) method was used to estimate the COI for 1996, 1999, 2002, 2005, 2008, and 2014 to make predictions for 2017, 2020, 2023, 2026, and 2029. The COI comprised direct and indirect costs (morbidity and mortality costs) of HCC.
resultsFrom 1996 to 2014, COI trended downward. In 2014, COI (579.2 billion JPY) was 0.71 times greater than that in 1996 (816.2 billion JPY). Mortality costs accounted for more than 70% of total COI and were a major contributing factor to the decrease in COI. It was predicted that COI would continue a downward trend until 2029, and that the rate of decline would be similar.
conclusionsCOI of HCC has been decreasing since 1996. Treatment of patients infected with hepatitis C virus using newly introduced technologies has high therapeutic effectiveness, and will affect the future prevalence of HCC. These policies and technologies may accelerate the downward tendency of COI, and the relative economic burden of HCC is likely to continue to decrease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.